신질환이 있는 경증 미치 중등도의 고혈압 환자에서 Irbesartan의 항고혈압효과 및 안전성을 평가하기 위한 제 4상 임상 시험

Irbesartan is a new selective angiotensin II subtype 1 receptor antagonist. We evaluated the efficacy and tolerability of irbesartan in patients with mild to moderate hypertension and renal disease. On 24 hypertensive patients, oral irbesartan 150mg a day was administered. In cases whose seated dias...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Kidney research and clinical practice 2000-07, Vol.19 (4), p.731
Hauptverfasser:	윤수영, Soo Young Yoon, 한승혁, Seung Hyuk Han, 박정엽, Jung Yeob Park, 송영수, Young Soo Song, 김병극, Byung Geuk Kim, 김주성, Joo Sung Kim, 노현정, Hyun Jung Nho, 노현진, Hyun Jin Nho, 신석균, Suk Gyun Shin, 최규헌, Gyu Hun Choi, 한대석, Dae Suk Han, 이호영, Ho Young Lee
Format:	Artikel
Sprache:	kor
Schlagworte:	Angiotnsin II receptor antagonist Hypertension Irbesartan Renal disease
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!